HOME >> MEDICINE >> NEWS
UI Study Yields Encouraging Results For New Breast Cancer Treatment

IOWA CITY, Iowa -- A University of Iowa Health Care treatment using high-dose chemotherapy followed by a bone marrow transplant may be more effective in fighting advanced breast cancer than standard treatment approaches -- despite recent reports of conflicting results from similar strategies tested elsewhere.

In the just-released issue of the journal Biology of Blood and Marrow Transplantation, UI researchers suggest that a four-drug, high-dose chemotherapy treatment along with a bone marrow transplant may improve survival for some women with stage IV breast cancer -- cancer that has spread beyond the breast.

"We have women who we treated with a bone marrow transplant up to 10 years ago who are still alive and free of cancer," said Roger Gingrich, M.D., Ph.D., UI professor of internal medicine and director of the Adult Bone Marrow Transplant Program at the UI Hospitals and Clinics. "We think it is very important for women with breast cancer to continue to carefully consider this treatment approach."

From May 1988 through May 1997, UI physicians treated 158 women with stage IV breast cancer using the four-drug, high-dose chemotherapy and bone marrow transplant strategy. Preliminary results indicate an overall survival rate of 38 percent.

At an American Society of Clinical Oncology (ASCO) meeting last week in Atlanta, researchers presented four studies that showed women with very risky or advanced breast cancer statistically did no better with the high-dose chemotherapy and bone marrow transplant treatment than those who received only low-dose chemotherapy. A fifth, relatively small study indicated that the high-dose chemotherapy/bone marrow transplant approach might work better. Each of the studies involved different drugs and doses.

In the two studies presented at the meeting that involved patients with chemotherapy-responsive stage IV breast cancer, the projected survival rates using the high-dose chemotherapy/transplant treatment were 32
'"/>

Contact: Jennifer Cronin
jennifer-cronin@uiowa.edu
319-335-9917
University of Iowa
28-May-1999


Page: 1 2 3

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Yields Encouraging Results For New Breast Cancer Treatment

(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
(Date:6/18/2013)... Daily Gossip Magazine has always kept its readers entertained ... , The magazine has decided to prepare readers for the ... recipe every week . , According to Daily Gossip ... readers who are looking to get insights into this type ... anabolic food is almost entirely based on healthy, yet tasteful ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 SEATTLE, WA—A ... Farms of Fairview, Oregon, claiming he fell ill with ... berry and pomegranate seed blend. The complaint was ... by Marler Clark, the Seattle-based law firm that has ... , According to the complaint, Brian Brothers consumed “Townsend ...
(Date:6/18/2013)... Warner, NH (PRWEB) June 18, 2013 ... rugged, submersible, battery powered, stand-alone device which can be ... The new stainless steel enclosure of the Temp1000IS comes ... device interfaces with the IFC400 (sold separately) ... docking station for full communications. No more removal of ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China and Taiwan ... first time in the U.S.—the need for more collaboration between ... in a timely manner. Representatives from the Taiwan and mainland ... and processes in drug review during the Convergence in ... DIA 2013 49th Annual Meeting . , While ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: